Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23455
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorTzouvara, E.en
dc.contributor.authorTsiara, S.en
dc.contributor.authorVartholomatos, G.en
dc.contributor.authorTsekeris, P.en
dc.contributor.authorBourantas, K.en
dc.date.accessioned2015-11-24T19:32:48Z-
dc.date.available2015-11-24T19:32:48Z-
dc.identifier.issn1075-122X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23455-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*adverse effectsen
dc.subjectBreast Neoplasms/*drug therapy/surgeryen
dc.subjectCarcinoma, Ductal, Breast/drug therapy/surgeryen
dc.subjectCarcinoma, Lobular/drug therapy/surgeryen
dc.subjectChemotherapy, Adjuvant/adverse effectsen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDiagnosis, Differentialen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFatal Outcomeen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectGranulocyte Colony-Stimulating Factor/administration & dosageen
dc.subjectHumansen
dc.subjectLeukemia, Myeloid, Acute/chemically induced/*diagnosisen
dc.subjectMethotrexate/administration & dosageen
dc.titleBiphenotypic acute leukemia following intensive adjuvant chemotherapy for breast cancer: case report and review of the literatureen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12752636-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1046/j.1524-4741.2003.09323.x/asset/j.1524-4741.2003.09323.x.pdf?v=1&t=h0t72svw&s=2dce5c8f42c19653f3df160a11193341d2c79134-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractThe risk of secondary leukemia in breast cancer patients who receive adjuvant chemotherapy is an open question. We describe the case a 38-year-old woman who developed acute leukemia 18 months after completion of intense adjuvant chemotherapy with prophylactic granulocyte colony-stimulating factor (G-CSF) support and chest wall irradiation. The diagnosis of biphenotypic T-cell acute myeloid leukemia (AML) was based on morphologic and immunophenotypic criteria. Chromosomal analysis of blasts revealed multiple trisomies and tetrasomies. The patient failed to respond to induction and salvage chemotherapy and died 4 months later. This case of acute leukemia occurred in a cohort of 65 high-risk breast cancer patients who were given intense adjuvant chemotherapy during the last 5 years in our hospital. This is the first case reported in the literature of acute leukemia following intense adjuvant chemotherapy with continuous prophylactic G-CSF, which is an actively investigated therapeutic strategy. Vigilance and investigation are needed to determine the leukemogenic potential of intense adjuvant chemotherapy plus radiotherapy in breast cancer patients. A brief review of the literature that deals with acute leukemia that develops after adjuvant chemotherapy for breast cancer and with secondary biphenotypic acute leukemia is presented.en
heal.journalNameBreast Jen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Briasoulis-2003-Biphenotypic acute l.pdf84.9 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons